Bavarian Nordic A/S, of Copenhagen, said it completed enrollment in a phase III study designed to demonstrate noninferiority between its investigational, nonreplicating smallpox vaccine, Imvamune, and ACAM2000, the current U.S. licensed, and replicating, smallpox vaccine.